In the case of prostate cancer, BRCA1 and BRCA2 mutations would lead to 8.6% and 15% cumulative risks respectively by age of 65 years (Thompson et al., 2002; Venkitaraman, 2002; Kote-Jarai et al., 2011; Leongamornlert et al., 2012). This evidence concerns the gene BRCA1 and Familial prostate cancer.